Vascular endothelial growth factor (VEGF)-A and VEGF-A

Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / blood Biomarkers / blood Churg-Strauss Syndrome / blood Cohort Studies Female Glucocorticoids / therapeutic use Granulomatosis with Polyangiitis / blood Humans Immunosuppressive Agents / therapeutic use Japan Male Microscopic Polyangiitis / blood Middle Aged Prospective Studies Remission Induction Vascular Endothelial Growth Factor A / blood
Antineutrophil cytoplasmic antibody-associated vasculitis rapidly progressive glomerulonephritis therapeutic efficacy vascular endothelial growth factor-A vascular endothelial growth factor-A165b

Journal

Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055

Informations de publication

Date de publication:
03 2021
Historique:
pubmed: 22 10 2020
medline: 7 7 2021
entrez: 21 10 2020
Statut: ppublish

Résumé

Effective prognostic markers are needed for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial growth factor-A (sVEGF-A) and sVEGF-A We collected samples from patients with AAV who were enrolled in the nationwide Japanese cohort study (RemIT-JAV-RPGN). We measured sVEGF-A and sVEGF-A Results revealed significant reductions in sVEGF-A and sVEGF-A These results suggest that sVEGF-A and -A

Sections du résumé

BACKGROUND
Effective prognostic markers are needed for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial growth factor-A (sVEGF-A) and sVEGF-A
METHODS
We collected samples from patients with AAV who were enrolled in the nationwide Japanese cohort study (RemIT-JAV-RPGN). We measured sVEGF-A and sVEGF-A
RESULTS
Results revealed significant reductions in sVEGF-A and sVEGF-A
CONCLUSION
These results suggest that sVEGF-A and -A

Identifiants

DOI: 10.1177/0004563220968371 PMID: 33081494
pubmed: 33081494
doi: 10.1177/0004563220968371
doi:

Substances chimiques

Biomarkers 0
Glucocorticoids 0
Immunosuppressive Agents 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-94

Auteurs

Ryosuke Kikuchi (R)

Department of Medical Technique, Nagoya University Hospital, Nagoya, Japan.
ORCID: 0000-0002-9403-4302

Naotake Tsuboi (N)

Department of Nephrology, School of Medicine, Fujita Health University, Nagoya, Japan.

Ken-Ei Sada (KE)

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.

Masahiro Nakatochi (M)

Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yuki Yokoe (Y)

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Atsuo Suzuki (A)

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Shoichi Maruyama (S)

Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Toyoaki Murohara (T)

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Tadashi Matsushita (T)

Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan.
Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.

Koichi Amano (K)

Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

Tatsuya Atsumi (T)

Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.

Yoshinari Takasaki (Y)

Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Satoshi Ito (S)

Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan.

Hitoshi Hasegawa (H)

Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan.

Hiroaki Dobashi (H)

Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Takafumi Ito (T)

Division of Nephrology, Shimane University, Faculty of Medicine, Shimane, Japan.

Hirofumi Makino (H)

Okayama University, Okayama, Japan.

Seiichi Matsuo (S)

Nagoya University, Nagoya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Syndrome de Churg-Strauss › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Glucocorticoïdes › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Granulomatose avec polyangéite › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Régions géographiques › Iles › Japon › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Vascularites associées aux anticorps anti-cytoplasme des neutrophiles › Polyangéite microscopique › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Thérapeutique › Induction de rémission › Vascular endothelial growth factor (VEGF)-A and VEGF-A
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type A › Vascular endothelial growth factor (VEGF)-A and VEGF-A